Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen, Inc. (NASDAQ: OPGN) regularly issues news and regulatory updates that describe its activities in precision medicine, molecular diagnostics, and bioinformatics for infectious disease and antimicrobial resistance. This news page aggregates those disclosures so readers can review how the company presents its business focus, collaborations, financings, and operational changes over time.
Company announcements have covered topics such as research and development collaborations involving antimicrobial resistance panels and genomic surveillance, feature releases for the AREScloud platform, and work related to the Unyvero systems and ARES Technology Platform. OpGen’s releases also discuss financial performance, cash management initiatives, and its own statements about substantial doubt regarding its ability to continue as a going concern, along with potential strategic alternatives it is considering.
Investors and observers can also find information here on equity and financing transactions, including preferred stock financings, warrant inducement agreements, and a securities purchase agreement that allows OpGen to sell common stock to an investor over time. Additional news items describe insolvency proceedings of subsidiaries Curetis GmbH and Ares Genetics GmbH, the sale of their assets by insolvency trustees, and agreements to transfer commercial customer contracts and installed Unyvero systems.
Corporate governance and management changes are another recurring theme in OpGen’s news, including appointments and resignations of directors and executive officers and a 1‑for‑10 reverse stock split intended, according to the company, to support compliance with Nasdaq’s minimum bid price requirement. This page allows readers to follow these developments through the company’s own published statements.
OpGen announced the continuation of its prospective multicenter trial for the Unyvero UTI panel after an interim analysis of the first 150 U.S. patient samples showed no significant performance variations. The reproducibility study was successfully completed, confirming the protocol's implementation across sites. The clinical evaluation aims for FDA submission, and enrollment is ongoing, targeting 1,500 samples. Archived urine samples will also be included to enhance data on rare pathogens and antimicrobial resistance.
OpGen reported a total revenue of approximately $4.3 million for 2021, a 2% increase from 2020. The fourth quarter revenue reached $1.43 million, reflecting a 5% growth year-over-year. Operating expenses for the year were around $27.6 million, leading to a net loss of $42 million, or $1.14 per share. However, cash reserves improved significantly to $36.1 million. The company anticipates 25% to 50% revenue growth in 2022, led by strong sales of its Unyvero and Acuitas product lines.
OpGen, Inc. (NASDAQ: OPGN) announced a business update alongside its fourth quarter and full year 2021 financial results to be reported after the U.S. markets close on March 29, 2022. A live conference call and audio webcast will take place at 4:30 PM ET to discuss financial outcomes and business updates. Following the call, a replay will be available until April 12, 2022. OpGen specializes in molecular diagnostics and bioinformatics to tackle infectious diseases, focusing on solutions for multidrug-resistant microorganisms.
OpGen, Inc. (Nasdaq: OPGN) announced a new publication demonstrating that the Acuitas AMR Gene Panel effectively detects 28 antimicrobial resistance (AMR) markers linked to various antimicrobial classes. This FDA-cleared diagnostic tool delivers results within 2.5 hours, significantly faster than traditional methods, aiding in patient management and antibiotic stewardship. The study showed a positive agreement of ≥ 94.4% and negative agreement of ≥ 96.5% compared to whole genome sequencing standards. This innovation marks a milestone in combating AMR pathogens in clinical settings.
OpGen, a precision medicine company, announced a significant milestone with its Unyvero A30 RQ platform. The instruments successfully completed verification and validation (V&V) testing, meeting all required criteria for series production. This achievement was supported by extensive lifetime testing of mechanical components, with rigorous stress conditions applied, including almost 1 million PCR cycles. CEO Oliver Schacht highlighted the readiness for clinical trials and regulatory submissions later in 2022. This development paves the way for future partnerships and commercialization efforts in the healthcare sector.
OpGen, a precision medicine company, announces its participation in Edison Group's virtual Open House Event from January 25-27, 2022. This three-day event, organized in collaboration with the London Stock Exchange and others, will showcase 33 companies. Each day will focus on different sectors: pharmaceuticals and drug discovery, AI and technology in healthcare, and innovative solutions for complex problems. Content will be available on-demand starting January 27, with registration details provided. OpGen aims to enhance diagnostic solutions for infectious diseases.
OpGen reported preliminary unaudited revenue of approximately $4.3 million for 2021, slightly up from $4.2 million in 2020. The fourth-quarter revenue was stable at $1.4 million, despite exiting the FISH business, which had contributed $0.7 million in Q4 2020. The company boasts a strong cash position with $36.1 million as of December 31, 2021. Key developments included the conversion of 150,000 preferred shares into 7.5 million common shares, and advancements in clinical trials and partnerships aimed at addressing antimicrobial resistance.
OpGen, Inc. (Nasdaq: OPGN) announced that its subsidiary, Ares Genetics, has successfully completed Phase 1 of its collaboration with a leading U.S. CRO and reference lab and is now entering Phase 2. This phase grants access to 1,000 proprietary clinical isolates aimed at enriching ARESdb, which has grown over 40% in the past year. Ares employs AI to predict antibiotic resistance, crucial for addressing the public health threat of antimicrobial resistance (AMR). The company expects this collaboration to enhance its offerings and drive growth in 2022.
OpGen, Inc. (Nasdaq: OPGN) announced stockholder approval for two key proposals at its Special Meeting on December 8, 2021. The first proposal modifies the approval requirement for changes to the Amended Certificate of Incorporation to a majority of outstanding shares. The second proposal increases the authorized shares of common stock from 50 million to 100 million. Approximately 99.3% of voting power supported the first proposal, while 79.8% favored the second. CEO Oliver Schacht remarked that this flexibility is crucial for future growth and capital raising.
Ares Genetics, a subsidiary of OpGen, Inc. (OPGN), announced a strategic agreement granting a global leader in microbiology permanent access to approximately 1.1% of its proprietary ARESdb data. This transaction focuses on specific pathogens related to resistant bacterial infections and includes a one-time fee. The deal highlights the value of ARESdb, which houses extensive antimicrobial resistance (AMR) data. Ares Genetics aims to use its AI capabilities for AMR marker discovery and genomic data analysis to combat infections, crucial in addressing public health threats from AMR.